Add to ORKGThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. Open Access Full open access to this and thousands of other papers a
Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to u...
Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (RCC) based on the results ...
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of...
which permits unrestricted noncommercial use, provided the original work is properly cited. Cancer M...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonComme...
Sorafenib in the management of metastatic renal cell carcinoma C. Guevremont bSc, C. Jeldres md, P. ...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic re...
<p>The performed study compared the toxic effects caused by the administration of sorafenib with the...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
www.karger.com/cro This is an Open Access article licensed under the terms of the Creative Commons A...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to u...
Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (RCC) based on the results ...
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of...
which permits unrestricted noncommercial use, provided the original work is properly cited. Cancer M...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonComme...
Sorafenib in the management of metastatic renal cell carcinoma C. Guevremont bSc, C. Jeldres md, P. ...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic re...
<p>The performed study compared the toxic effects caused by the administration of sorafenib with the...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
www.karger.com/cro This is an Open Access article licensed under the terms of the Creative Commons A...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to u...
Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (RCC) based on the results ...
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of...